摘要慢性粒细胞白血病(CML)是一种发生在骨髓多功能造血干细胞上的恶性增殖性疾病.目前,伊马替尼用于CML的一线治疗,不但对慢性期的患者疗效显著,而且对于加速期和急变期患者也同样能够明显延长其生存时间.随着伊马替尼在临床上的长期应用,逐渐出现了耐药及不耐受现象,因此降低了CML的长期治疗效果.文章就CML的发病机制及治疗现状进行综述.

abstractsChronic myeloid leukemia (CML) is a malignant clonal proliferative disease,which originates from multifunctional hematopoietic stem cells of bone marrow.Imatinib is used as the first-line treatment for CML currently,owing to its obvious curative effect for patients in chronic phase and survival time prolonged significantly for patients in accelerated phase and blast crisis.With the long-term application of imatinib in clinic,the drug resistance and intolerance gradually appear,resulting in decreased long-term effects of CML.This paper will review the current status of the pathogenesis and treatment of CML.